{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:04Z","timestamp":1792804144768,"version":"4.5.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["TCRC grant"],"award-info":[{"award-number":["TCRC grant"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001036","name":"Australian Rotary Health","doi-asserted-by":"publisher","award":["PhD scholarship"],"award-info":[{"award-number":["PhD scholarship"]}],"id":[{"id":"10.13039\/501100001036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211866","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T18:32:28Z","timestamp":1549650748000},"page":"e0211866","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status"],"prefix":"10.1371","volume":"14","author":[{"given":"Joseph W.","family":"Po","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bavanthi","family":"Balakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5636-9902","authenticated-orcid":true,"given":"Therese M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"ref1","article-title":"Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration","author":"WL Hwang","year":"2018","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy","volume":"6","author":"C Alix-Panabieres","year":"2016","journal-title":"Cancer Discovery"},{"key":"ref3","article-title":"Liquid biomarkers in melanoma: detection and discovery","volume":"17","author":"SY Lim","year":"2018","journal-title":"Molecular Cancer"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"M Gerlinger","year":"2012","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2016.02.024","article-title":"Tumor heterogeneity and circulating tumor cells","volume":"374","author":"C Zhang","year":"2016","journal-title":"Cancer Letters"},{"issue":"40","key":"ref6","doi-asserted-by":"crossref","first-page":"67355","DOI":"10.18632\/oncotarget.18641","article-title":"Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device","volume":"8","author":"CA Aya-Bonilla","year":"2017","journal-title":"Oncotarget"},{"issue":"39","key":"ref7","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"ES Gray","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"JH Lee","year":"2017","journal-title":"Annals of Oncology"},{"issue":"224","key":"ref9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"C Bettegowda","year":"2014","journal-title":"Science Translational Medicine"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/0008-5472.CAN-05-4198","article-title":"Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients","volume":"66","author":"K Koyanagi","year":"2006","journal-title":"Cancer Research"},{"key":"ref11","article-title":"Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma","volume":"2","author":"F Salvianti","year":"2015","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/0008-5472.CAN-13-1739","article-title":"Universal marker and detection tool for human sarcoma circulating tumor cells","volume":"74","author":"A Satelli","year":"2014","journal-title":"Cancer Research"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2159-8290.CD-14-0471","article-title":"Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression","volume":"4","author":"JP Sullivan","year":"2014","journal-title":"Cancer Discovery"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000372-199406000-00003","article-title":"Epithelial markers in malignant melanoma. A study of primary lesions and their metastases","volume":"16","author":"O Ben-Izhak","year":"1994","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"TM Grzywa","year":"2017","journal-title":"Translational Oncology"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/jid.2015.127","article-title":"Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment","volume":"135","author":"ES Gray","year":"2015","journal-title":"The Journal of Investigative Dermatology"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14728214.2016.1184644","article-title":"Emerging targeted therapies for melanoma","volume":"21","author":"DB Johnson","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref18","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact","author":"H Rizos","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"JD Wolchok","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"ref20","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"MA Postow","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"7528","key":"ref21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"RS Herbst","year":"2014","journal-title":"Nature"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejso.2016.07.014","article-title":"Immunotherapy of melanoma","volume":"43","author":"D Kee","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of response to PD-1\/PD-L1 inhibition","volume":"116","author":"S Maleki Vareki","year":"2017","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"MW Teng","year":"2015","journal-title":"Cancer Research"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"e0123410","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB","volume":"10","author":"K Gowrishankar","year":"2015","journal-title":"PloS one"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1479-5876-10-192","article-title":"Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells","volume":"10","author":"JB Freeman","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bjps.2007.04.010","article-title":"Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy","volume":"61","author":"RA Pearl","year":"2008","journal-title":"Journal of Plastic, Rconstructive & Aesthetic Surgery"},{"issue":"3","key":"ref28","first-page":"755","article-title":"Circulating melanoma cells and survival in metastatic melanoma","volume":"38","author":"C Rao","year":"2011","journal-title":"International Journal of Oncology"},{"key":"ref29","article-title":"Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma","author":"L Khoja","year":"2012","journal-title":"The Journal of Investigative Dermatology"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.2012.12","article-title":"Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level","volume":"106","author":"K Sakaizawa","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jamcollsurg.2018.04.026","article-title":"Circulating Tumor Cells in Stage IV Melanoma Patients","volume":"227","author":"CS Hall","year":"2018","journal-title":"J Am Coll Surg"},{"key":"ref32","article-title":"Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin","volume":"7","author":"JW Po","year":"2018","journal-title":"Journal of Circulating Biomarkers"},{"issue":"19","key":"ref33","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/0008-5472.CAN-08-4626","article-title":"Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition","volume":"69","author":"J Yang","year":"2009","journal-title":"Cancer Research"},{"issue":"26","key":"ref34","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"JA Curtin","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12254-016-0292-2","article-title":"PD-L1 testing, fit for routine evaluation? From a pathologist's point of view","volume":"9","author":"G Hutarew","year":"2016","journal-title":"Memo"},{"key":"ref36","article-title":"Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma","author":"ER Parra","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/his.13056","article-title":"Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system","volume":"70","author":"KA Schats","year":"2017","journal-title":"Histopathology"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1186\/s12885-016-2758-3","article-title":"Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients","volume":"16","author":"A Anantharaman","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"ref39","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/jid.2010.117","article-title":"Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes","volume":"130","author":"TM Becker","year":"2010","journal-title":"The Journal of Investigative Dermatology"},{"key":"ref40","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","author":"RE Vilain","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","article-title":"Frequent expression of PD-L1 on circulating breast cancer cells","volume":"9","author":"M Mazel","year":"2015","journal-title":"Molecular Oncology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab","volume":"6","author":"C Nicolazzo","year":"2016","journal-title":"Scientific Reports"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T04:50:59Z","timestamp":1606452659000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211866"}},"subtitle":[],"editor":[{"given":"Nikolas K.","family":"Haass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211866","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]}}}